Indeed, there has been considerable interest in the development of FASN inhibitors, which include the next‐generation therapeutics such as TVB‐2640 and yields high anti‐tumor potential and limited systematic toxicity in clinical trials. The gene discussed is FASN; the disease is neoplasm.